03Dec 2024
Noiiglutide Trial Shows Promising Weight Loss Results in Obesity

Noiiglutide Trial Shows Promising Weight Loss Results in Obesity

In a phase 1 trial, noiiglutide (SHR20004), a GLP-1 receptor agonist, demonstrated safety and efficacy for weight loss in Chinese obese participants without diabetes. Administered daily using a titration method, it exhibited a favorable safety profile with no serious adverse events. Pharmacokinetics showed steady-state concentration within 4 days and a half-life of 9.90–11.8 h. Dose-dependent reductions in weight and BMI were observed, with mean weight loss reaching −7.46 kg in the highest dose group. These findings highlight noiiglutide's potential as a therapeutic option for obesity management.

  • #business

Like

Save

Share